# Leuprolide in the treatment of endometrial cancer.

> PubMed lists PMID 9299275 in Gynecologic oncology as Letter, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9299275-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9299275-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-9299275-leuprolide-v1.json
- Content SHA-256: `fe241598ed00340fb9631a334d771ff9a31693414c0c2d236de0a3cc702e3d4a`

## Claims and source pins

### Headline

Leuprolide in the treatment of endometrial cancer. ([`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`](#source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d))

### Summary

PubMed lists PMID 9299275 in Gynecologic oncology as Letter, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`](#source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d))

### Paragraph 1

PubMed lists PMID 9299275 in Gynecologic oncology as Letter, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`](#source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`](#source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d))

## Sources

<a id="source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d"></a>
- **Leuprolide in the treatment of endometrial cancer. · retained source version 1:2013-11-21:current:8d5da1f0ef9da0108a0e3d229168a67c1a5779048a2a99c2260b4121dafe229a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9299275/) (`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Leuprolide in the treatment of endometrial cancer." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-9299275-leuprolide-v1.json SHA-256: fe241598ed00340fb9631a334d771ff9a31693414c0c2d236de0a3cc702e3d4a.